Paclitaxel (Taxol)
Eric Keith Rowinsky, Ross C. Donehower · New England Journal of Medicine · 1995
The taxanes are an important new class of anticancer agents that exert their cytotoxic effects through a unique mechanism. Paclitaxel (Taxol), the first taxane in clinical trials, is active against a broad range of cancers that are generally considered to be refractory to conventional chemotherapy. This has led to the regulatory approval of paclitaxel in the United States and many other countries for use in the palliative therapy of patients with ovarian and breast cancers resistant to chemotherapy. The challenge now is to develop strategies using paclitaxel in the initial therapy of cancers in which cure or improved survival may . . .
Cited by 1,873 works. doi:10.1056/nejm199504133321507
Authors
References
- Promotion of microtubule assembly in vitro by taxol
- Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia
- Taxol stabilizes microtubules in mouse fibroblast cells.
- Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms
- Taxol: A Novel Investigational Antimicrotubule Agent
- Hypersensitivity reactions from taxol.
- European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
- Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.
- Taxol binds to polymerized tubulin in vitro